Galecto Reports First Quarter Operating and Financial Results
Galecto, Inc. (NASDAQ: GLTO) reported its financial results for Q1 2022, highlighting significant progress in clinical trials. The company completed enrollment in two Phase 2 trials—GALACTIC-1 for idiopathic pulmonary fibrosis (IPF) and GULLIVER-2 for liver cirrhosis. The total net loss increased to $16.9 million, or $(0.67) per share, from $13.3 million, or $(0.53) per share, year-over-year. As of March 31, 2022, Galecto had approximately $101.8 million in cash and equivalents, expected to fund operations into late 2024.
- Completed enrollment in GALACTIC-1 and GULLIVER-2 Phase 2 clinical trials.
- Strong cash position of $101.8 million, sufficient to fund operations into late 2024.
- Net loss increased to $16.9 million in Q1 2022 compared to $13.3 million in Q1 2021.
- R&D expenses rose to $13.2 million, up from $10.0 million, mainly due to increased clinical trial costs.
BOSTON, April 29, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced its operating and financial results for the quarter ended March 31, 2022.
“We continued to execute this quarter, and importantly completed enrollment in two of our three ongoing Phase 2 trials: GALACTIC-1 in IPF and GULLIVER-2 in liver cirrhosis,” said Hans Schambye, CEO of Galecto. “As we await topline data from GULLIVER-2 later this year, we look forward to other important milestones, including initiating enrollment in GALLANT-1, our Phase 2 trial in first-line NSCLC, and completing enrollment in MYLOX-1, our Phase 2 trial in myelofibrosis. We look forward to multiple data read-outs over the next year from our broad clinical stage pipeline and remain optimistic and focused on progressing all our clinical projects .”
Recent Highlights
- Completed target enrollment of 141 patients in the GALACTIC-1 Phase 2b clinical trial in idiopathic pulmonary fibrosis (IPF).
- Completed enrollment of Parts 2 and 3 of the GULLIVER-2 trial in liver cirrhosis. Part 2 of the trial is designed to assess the effect of 12-week dosing of GB1211 on a wide series of biological markers of hepatic function and structure in participants with moderate hepatic impairment; and Part 3 of the GULLIVER-2 trial is designed to evaluate patients with liver cirrhosis and severe hepatic impairment.
Expected Upcoming Milestones
- Initiation of enrollment in Phase 2a GALLANT-1 trial of GB1211 in combination with Tecentriq® in first-line Non-Small-Cell Lung Cancer in Q2 2022.
- Interim readout of MYLOX-1 trial in mid-2022 followed by completion of enrollment in 2H 2022.
- Top-line results from Parts 2 and 3 of the GULLIVER-2 Phase 1b/2a trial in Q4 2022.
First Quarter 2022 Financial Highlights
Cash, cash equivalents, and investments as of March 31, 2022 were approximately
Research and development expenses were
General and administrative expenses were
Net loss attributable to common stockholders for the three months ended March 31, 2022 was
About Galecto
Galecto is a clinical stage company incorporated in the U.S. that is developing small molecule-based inhibitors of galectin-3 (and the galectin family generally) and LOXL2. Galecto has multiple ongoing Phase 2 clinical programs in fibrosis and cancer, including (i) an inhaled galectin-3 modulator (GB0139) in a phase 2b trial for the treatment of idiopathic pulmonary fibrosis (IPF); (ii) an orally active LOXL2 inhibitor (GB2064) in a phase 2a trial for the treatment of myelofibrosis; (iii) an orally active galectin-3 inhibitor (GB1211) in a phase 1b/2a trial in liver cirrhosis and a separate planned phase 2a trial for the treatment of NSCLC in combination with atezolizumab (Tecentriq®).
Galecto intends to use its website as a means of disclosing material non-public information. For regular updates about Galecto, visit www.galecto.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Galecto’s ability to make progress across its clinical pipeline of asset; the potential of Galecto’s product candidates to address significant areas of unmet need; Galecto’s plans for timing of completing enrollment in its MYLOX-1 and GULLIVER-2 trials; Galecto’s plans for initiating its GALLANT-1 trial, and Galecto’s expectation that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital requirements into the second half 2024. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. For such statements, Galecto claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Galecto's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include risks and uncertainties related to the development of Galecto’s product candidates and their therapeutic potential, having adequate funds and their use, and those disclosed in Galecto’s filings with the Securities and Exchange Commission (SEC), including, but not limited to, Galecto’s Annual Report on Form 10-K, as filed with the SEC on February 17, 2022. These forward-looking statements represent Galecto's judgment as of the time of this release. Galecto disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.
For more information, contact:
| Galecto, Inc. | |
| Hans Schambye, CEO Jon Freve, CFO | |
| +45 70 70 52 10 | |
Investors/US | Media/EU |
| Ashley R. Robinson arr@lifesciadvisors.com | Sandya von der Weid svonderweid@lifesciadvisors.com |
| +1 617 430 7577 | +41 78 680 0538 |
Financial Tables to Follow
GALECTO, INC.
Condensed Consolidated Balance Sheets
(in thousands)
| March 31, | December 31, | ||||
| 2022 | 2021 | ||||
| (unaudited) | |||||
| Cash and cash equivalents | $ | 45,388 | $ | 62,563 | |
| Marketable securities | 48,210 | 37,628 | |||
| Prepaid expenses and other current assets | 3,434 | 9,911 | |||
| Marketable securities, noncurrent | 8,160 | 9,048 | |||
| Operating lease right-of-use assets | 702 | 834 | |||
| Other assets, noncurrent | 3,036 | 2,231 | |||
| Total assets | $ | 108,930 | $ | 122,215 | |
| Current liabilities | $ | 7,214 | $ | 4,544 | |
| Operating lease liabilities, noncurrent | 402 | 448 | |||
| Total liabilities | 7,616 | 4,992 | |||
| Total stockholders’ equity | 101,314 | 117,223 | |||
| Total liabilities and stockholders' equity | $ | 108,930 | $ | 122,215 | |
GALECTO, INC.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
(unaudited)
| For the Three Months Ended March 31, | |||||||
| 2022 | 2021 | ||||||
| Operating expenses: | |||||||
| Research and development | $ | 13,235 | $ | 9,990 | |||
| General and administrative | 3,704 | 3,562 | |||||
| Total operating expenses | 16,939 | 13,552 | |||||
| Loss from operations | (16,939 | ) | (13,552 | ) | |||
| Total other income (expense), net | 1 | 207 | |||||
| Net loss | $ | (16,938 | ) | $ | (13,345 | ) | |
| Net loss per common share, basic and diluted | $ | (0.67 | ) | $ | (0.53 | ) | |
| Weighted-average number of shares used in computing net loss per common share, basic and diluted | 25,261,832 | 25,261,832 | |||||
| Other comprehensive loss, net of tax | (375 | ) | (604 | ) | |||
| Total comprehensive loss | $ | (17,313 | ) | $ | (13,949 | ) | |
FAQ
What were Galecto's net loss and EPS for Q1 2022?
What is the cash position of Galecto as of March 31, 2022?
What clinical trials has Galecto completed enrollment for recently?
When does Galecto expect to release topline data for GULLIVER-2?
